Mariona Xercavins

Dr. Mariona Xercavins


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
ESElena Salamanca
Elena Salamanca
MCMarina de Cueto
Marina de Cueto
PHPo-Ren Hsueh
Po-Ren Hsueh
PVPierluigi Viale
Pierluigi Viale
EJE Jové
E Jové

8 January 2019 in Microbial Drug Resistance
Verified
Journal Article
Open access
VLVirginio Cepas Lopez
Virginio Cepas Lopez
YLYuly Lopez
Yuly Lopez
EMEstela Muñoz
Estela Muñoz
DRDora Rolo
Dora Rolo
CACarmen Ardanuy
Carmen Ardanuy
SSSara M. Soto
Sara M. Soto
Gram-negative microorganisms are a significant cause of infection in both community and nosocomial settings. The increase, emergence, and spread of antimicrobial resistance among bacteria are the most important health problems worldwide. One of the mechanisms of resistance used by bacteria is biofilm formation, which is also a mechanism of virulence. This study analyzed the possible relationship between antimicrobial resistance and biofilm formation among isolates of three Gram-negative bacteria species. Several relationships were found between the ability to form biofilm and antimicrobial resistance, being different for each species. Indeed, gentamicin and ceftazidime resistance was related to biofilm formation in Escherichia coli , piperacillin/tazobactam, and colistin in Klebsiella pneumoniae , and ciprofloxacin in Pseudomonas aeruginosa . However, no relationship was observed between global resistance or multidrug-resistance and biofilm formation. In addition, compared with other reported data, the isolates in the present study showed higher rates of antimicrobial resistance. In conclusion, the acquisition of specific antimicrobial resistance can compromise or enhance biofilm formation in several species of Gram-negative bacteria. However, multidrug-resistant isolates do not show a trend to being greater biofilm producers than non-multiresistant isolates.

1 March 2011 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ECEsther Calbo
Esther Calbo
NFNúria Freixas
Núria Freixas
MXMariona Xercavins
Mariona Xercavins
MRMontserrat Riera
Montserrat Riera
CNCarmen Nicolás
Carmen Nicolás
JGJavier Garau
Javier Garau
Background. We describe a foodborne nosocomial outbreak due to extended-spectrum β-lactamase (ESBL)–producing Klebsiella pneumoniae. Methods.An outbreak of ESBL K. pneumoniae was detected in March 2008. Initial control measures included contact isolation and a protocol for routine detection and reinforcement in hand hygiene practices. ESBL producers were screened for the blaTEM, blaSHV, and blaCTX-M genes. Pulsed-field gel electrophoresis analysis was performed using XbaI as a restriction endonuclease. Results. One hundred fifty-six colonized and/or infected patients were identified, 35 (22.4%) of whom had infection. The outbreak affected all hospital wards. Fecal carriage was up to 38% of patients in some wards. Of note, investigation revealed a very short delay between admission and colonization. None of the health care workers or environmental surfaces in the wards was found to be colonized. This prompted an epidemiological investigation of a possible foodborne transmission. We found that up to 35% of the hospital kitchen–screened surfaces or foodstuff were colonized and that 6 (14%) of 44 food handlers were found to be fecal carriers. Phenotypic and genotypic analysis of all clinical, environmental, and fecal carrier isolates showed the dissemination of a single strain of SHV-1 and CTX-M-15–producing K. pneumoniae. At that time, structural and functional reforms in the kitchen were performed. These were followed by a progressive reduction in colonization and infection rates among inpatients until complete control was obtained in December 2008. No restrictions in the use of antibiotics were needed. Conclusions. To our knowledge, this is the first reported hospital outbreak that provides evidence that food can be a transmission vector for ESBL K. pneumoniae.

1 October 2016 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
ESElena Salamanca
Elena Salamanca
MCMarina de Cueto
Marina de Cueto
PHPo-Ren Hsueh
Po-Ren Hsueh
PVPierluigi Viale
Pierluigi Viale
EJE. Jové
E. Jové

9 October 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
OGOriol Gasch
Oriol Gasch
MCM. Camoez
M. Camoez
MDMaria Ángeles Domínguez
Maria Ángeles Domínguez
BPB. Padilla
B. Padilla
VPV. Pintado
V. Pintado
NLNieves Larrosa
Nieves Larrosa

12 May 2016 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
IMIrene Merino
Irene Merino
ESEvelyn Shaw
Evelyn Shaw
JHJuan Pablo Horcajada
Juan Pablo Horcajada
ECEmilia Cercenado
Emilia Cercenado
BMBeatriz Mirelis
Beatriz Mirelis
VPV. Pintado
V. Pintado
The objective of this study was to assess the prevalence and molecular epidemiology of ESBL-producing Escherichia coli causing healthcare-associated (HCA) and community-associated (CA) bacteraemia of urinary origin (BUO) in Spain. An observational cohort study was conducted at eight hospitals from different Spanish geographical areas (2010–11). BUO episodes (n = 425) were classified as HCA (n = 215) and CA (n = 210), and one blood isolate per episode was collected. Susceptibility testing was performed, ESBLs were screened by double-disc diffusion test and ESBL and OXA-1 genes were characterized (PCR and sequencing). Population structure (phylogenetic groups, XbaI-PFGE and MLST) and ST131 subtyping (PCR) were determined. Virulence genes were detected by PCR and virulence score, profiles and extraintestinal pathogenic E. coli (ExPEC) status calculated. ESBL-producing E. coli prevalence was 9.2% (39/425). ESBL-producing E. coli episodes were significantly associated with HCA-BUO episodes [14% (30/215) versus 4.3% (9/210); P = 0.001]. The highest non-susceptibility proportions corresponded to ciprofloxacin (97.4%), amoxicillin/clavulanate (74.4%), co-trimoxazole (69.2%) and tobramycin (61.5%). Of the 39 ESBL-producing E. coli isolates, 34 produced CTX-M enzymes (21 CTX-M-15, 11 CTX-M-14 and 2 CTX-M-1). Fifteen STs were identified, the B2-ST131 clone being the most prevalent (54%; 21/39). All ST131 isolates were ExPEC and had the highest virulence scores, but they showed less diversity in virulence profiles than other STs. The H30Rx subclone accounted for most ST131 isolates (20/21), co-produced CTX-M-15 (20/20) and OXA-1 (19/20) enzymes and was associated with HCA episodes (16/20). The CTX-M-15-ST131-H30Rx subclone is a relevant MDR pathogen causing BUO, mainly HCA episodes. The dominance of this subclone with comparatively less diversity of virulence profiles reflects the spread of a successful and MDR ESBL ST131 lineage in Spain.